You Save:
Inclusive of all taxes
Prices converted to INR (Indian Rupees) are approximate and may vary based on current currency exchange rates.
Product not available
SOKALT – Sorafenib 200 mg Tablets
Sorafenib 200 mg Tablets
Composition: Sorafenib Tablets 200 mg
Dosage Form: Tablets
Packing: 30 Tablets
Market Authorization: MBA Pharmaceuticals Pvt Ltd
Country of Origin: India
Country Of Origin : India
Product Introduction
SOKALT – Sorafenib 200 MG Tablets
SOKALT Tablet belongs to the class of medicines known as tyrosine kinase inhibitors and is used in the treatment of liver cancer, kidney cancer, and thyroid cancer.
Administration and Dosage
SOKALT – Sorafenib 200 mg tablet should be taken on an empty stomach, ideally at the same time every day to maximize its benefits. Your doctor will determine the appropriate dosage and frequency based on the specific condition being treated, and this may be adjusted over time. It’s crucial to follow your doctor’s instructions precisely. Incorrect use or overdose can lead to serious side effects. It may take several weeks or months to experience the full benefits, so continue taking it as directed unless your doctor advises otherwise.
Common Side Effects
Common side effects of Sorafenib Tablet include:
Fatigue
Nausea
Loss of appetite
Hair loss
Diarrhea
This medication may also cause high blood pressure, so your doctor may recommend regular blood pressure monitoring. Be sure to inform your doctor if you experience severe skin reactions such as a rash, or if you notice pain, swelling, or redness in your hands and feet.
Precautions
Before starting SOKALT Tablet, inform your doctor if you have any heart conditions, liver or kidney problems, or high blood pressure. This medicine can interact with other medications, so it’s important to inform your healthcare team about all the medicines you are taking. SOKALT Tablet is not recommended during pregnancy or while breastfeeding, and it is important for both males and females to use effective contraception during treatment to prevent pregnancy.